Singapore markets closed

EyePoint Pharmaceuticals, Inc. (EYPT)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
9.38+0.09 (+0.97%)
At close: 04:00PM EDT
9.56 +0.18 (+1.92%)
After hours: 07:02PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close9.29
Open9.19
Bid9.37 x 600
Ask9.42 x 500
Day's range9.11 - 9.49
52-week range5.67 - 30.99
Volume521,861
Avg. volume1,109,698
Market cap488.552M
Beta (5Y monthly)1.60
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    EyePoint Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference

    WATERTOWN, Mass., June 05, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint Pharmaceuticals will present at the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, 2024 at 3:20 p.m. ET. A live webcast and subsequent archived

  • GlobeNewswire

    EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    WATERTOWN, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an a

  • GlobeNewswire

    EyePoint Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Developments

    – Company on track to initiate the Phase 3 LUGANO pivotal non-inferiority trial of DURAVYU™ in wet AMD in 2H 2024 – – $299 million of cash and investments on March 31, 2024, with cash runway through topline data of Phase 3 trials for DURAVYU for wet AMD in 2026 – – Company to host R&D Day in New York on June 26, 2024 – WATERTOWN, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the